Tests blood DNA monitoring during treatment for early diffuse large B cell lymphoma
Measures tumor DNA in blood during treatment in adults with early-stage lymphoma.
Plain-language title generated from the registry record
Registry title: A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
Key facts
- Where
- Rochester, United StatesSee the site
- Phase
- Phase 2
Where in United States
- University of RochesterRochester, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Rochester
- Trial code
- NCT03758989
- Record updated
- 13 October 2026
- Original description
The overarching goals of this study are to measure levels of circulating tumor DNA (ctDNA) in patients with early stage diffuse large B cell lymphoma (DLBCL), to assess the change in ctDNA during treatment in order to prospectively identify markers of treatment failure, and to use ctDNA as a future tool for response adapted therapy.Read full original descriptionShow less
A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
The overarching goals of this study are to measure levels of circulating tumor DNA (ctDNA) in patients with early stage diffuse large B cell lymphoma (DLBCL), to assess the change in ctDNA during treatment in order to prospectively identify markers of treatment failure, and to use ctDNA as a future tool for response adapted therapy.
Inclusion: Previously untreated limited stage non bulky DLBCL; defined as limited stage by routine staging criteria in lymphoma involving FDG-PET and bone marrow biopsies (the Lugano criteria)[21]; Patients with grade 3B follicular lymphoma and transformed indolent lymphoma are included; Ages ≥ 18; Measurable disease, assessable by radiographic examination with FDG-PET showing involvement; Access to archived or fresh/frozen tumor biopsies; No uncontrolled medical comorbidities; Adequate cardiac function (EF > or equal to 50%), no unstable angina; Adequate renal function (GFR > 60); Adequate liver function (liver function tests should be no greater than 2 x upper limit of normal) including normal bilirubin levels, no greater than 2 x upper limit of normal unless patient has a history of Gilbert's disease; Adequate marrow reserves as indicated by complete blood count in the judgment of the treating investigator.
Exclusion: Bulky disease greater than 10 cm in any dimension; Pregnancy, positive serum HCG within 28 days of enrollment, or breast-feeding.